Percival-Smith R K, Yuzpe A A, Desrosiers J A, Rioux J E, Guilbert E
Student Health Services, University of British Columbia, Vancouver.
Contraception. 1990 Sep;42(3):253-62. doi: 10.1016/0010-7824(90)90013-l.
Cycle control was studied comparing the monophasic oral contraceptive Loestrin with three low-dose phasic preparations (Triphasil, Ortho 10/11 and Ortho 7/7/7) in 391 women of whom 300 completed 6 cycles. Loestrin subjects had a rate of occurrence (31% of cycles) for intermenstrual bleeding (IMB) comparable to the rates for subjects on the phasic preparations (36%, 37% and 37%, respectively). Triphasil subjects had lower rates than the Ortho 10/11 and Ortho 7/7/7 subjects (p less than 0.01) in cycle one when all subjects were analyzed and in pre-study users when continuing menstrual flow (CMF) episodes were not included as IMB. IMB was a cause for dropping out of the study in 7% of subjects who were evenly distributed between groups. There were no differences between groups for BTB when perceived by subjects as a side effect. Spotting was perceived as a side effect more often with Ortho 10/11 and Ortho 7/7/7 use than with Triphasil (p less than 0.01). Loestrin, Ortho 10/11 and Ortho 7/7/7 subjects were more likely to report amenorrhea (p less than 0.001) and less likely to report leg cramps (p less than 0.01) compared to those on Triphasil. Triphasil subjects were less likely to report acne than subjects on Ortho 7/7/7 (p less than 0.01).
对391名女性进行了周期控制研究，比较单相口服避孕药炔雌醇/诺孕酯与三种低剂量三相制剂（复方三相口服避孕药、炔诺孕酮炔雌醇片10/11和炔诺孕酮炔雌醇片7/7/7），其中300名女性完成了6个周期。炔雌醇/诺孕酯组的经间期出血（IMB）发生率（31%的周期）与服用三相制剂的受试者的发生率（分别为36%、37%和37%）相当。在分析所有受试者的第一个周期以及在继续月经出血（CMF）发作未被视为IMB的研究前使用者中，复方三相口服避孕药组的发生率低于炔诺孕酮炔雌醇片10/11组和炔诺孕酮炔雌醇片7/7/7组（p<0.01）。IMB是7%的受试者退出研究的原因，这些受试者在各组之间分布均匀。当受试者将突破性出血（BTB）视为副作用时，各组之间没有差异。与复方三相口服避孕药相比，使用炔诺孕酮炔雌醇片10/11和炔诺孕酮炔雌醇片7/7/7时，点滴出血更常被视为副作用（p<0.01）。与服用复方三相口服避孕药的受试者相比，炔雌醇/诺孕酯组、炔诺孕酮炔雌醇片10/11组和炔诺孕酮炔雌醇片7/7/7组的受试者更有可能报告闭经（p<0.001），而报告腿部痉挛的可能性较小（p<0.01）。与炔诺孕酮炔雌醇片7/7/7组的受试者相比，复方三相口服避孕药组的受试者报告痤疮的可能性较小（p<0.01）。
